Pfizer Inc announced it has entered into an agreement to acquire CovX, a privately-held biotherapeutics company specializing in preclinical oncology and metabolic research and a developer of a biotherapeutics technology platform that will enhance Pfizer's biologic portfolio.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments